Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.32 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31529937 | 0.73 | MAPKAPK2 (0.60) | CDC7MAPKAPK2BUB1 | |
| SCHEMBL31529936 | 0.73 | MAPKAPK2 (0.60) | CDC7MAPKAPK2BUB1 | |
| SCHEMBL792914 | 0.72 | PARP10 (0.58) | CDC7MAPKAPK2PARP10PARP11CHRNB2 | |
| SCHEMBL9746621 | 0.68 | CDC7 (0.35) | CDC7MAPKAPK2CHRNB2CHRNA4PKN2 | |
| SCHEMBL15813775 | 0.67 | CDC7 (0.48) | CDC7MAPKAPK2PARP10PARP11CHRNB2 | |
| SCHEMBL4323285 | 0.63 | CYP1A2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL29792666 | 0.63 | CYP1A2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL460089 | 0.63 | CDC7 (0.39) | CDC7PARP10PARP11CHRNB2CHRNA4 | |
| SCHEMBL9746424 | 0.63 | SIGMAR1 (0.40) | CDC7BUB1CHRNB2CHRNA4PKN2 | |
| SCHEMBL793402 | 0.63 | PARP10 (0.58) | CDC7MAPKAPK2PARP10PARP11CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CDC7 977/4885MAPKAPK2 480/4885BUB1 1099/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CDC7 977/4885MAPKAPK2 480/4885BUB1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.